Noticias de LLY_US
Noticias del mercado
Últimas noticias sobre LLY_US — 1345 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
InnoCare Pharma y Eli Lilly firman una colaboración de investigación multimillonaria, la FDA aprueba a Lilly
BigHat Biosciences, a San Mateo, California-based biotechnology company developing AI-designed protein therapeutics, has raised a $75 million Series C financing co-led by DFJ Growth and Premji Invest, bringing its total funding to $223 million. The financing will support the company's clinical-stage drug pipeline and the continued development of its autonomous AI platform for protein design.
¿Qué pasó? Las acciones de la compañía farmacéutica mundial Eli Lilly (NYSE:LLY) subieron un 3,1% en la sesión de la tarde después de que la Administración de Alimentos y Medicamentos de EE.UU...
Eli Lilly and Company (NYSE:LLY) featured across healthcare coverage as acquisitions and regulatory clearances arrived amid a cautious market backdrop.
Lilly’s Ricks says state needs to emphasize quality of life, health care
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
Eli Lilly received FDA approval for Onswik, a once-weekly basal insulin for adults with type 2 diabetes.
Eli Lilly and Company (LLY) is up 3.6% today. Here is some analysis on what might have caused this p
Eli Lilly expands pharmaceutical research through an InnoCare collaboration while remaining a major S&P 500 Health Care constituent spanning multiple therapeutic areas worldwide.
Governor Greg Abbott delivered remarks at the groundbreaking ceremony for Eli Lilly and Company’s $6.5 billion active pharmaceutical ingredient (API) manufacturing site at Generation Park in Harris County.
The weekly insulin Onswik will now be available to U.S. patients after initial approvals in Europe, Mexico and Japan.
Amid a $50 billion plan to reshore medicine production, Eli Lilly broke ground on a $6.5 billion manufacturing plant in Houston, Texas.
Lilly wins FDA nod for once-weekly insulin product, Onswik
BigHat Biosciences Announces $75 Million Series C Financing to Advance AI-Designed Therapeutics and Leading Agentic Data Platform for Rapid Protein Design
Los estudios de más de 3400 adultos con diabetes tipo 2 encontraron que la reducción de A1C de Onswik no fue inferior a la insulina diaria; La pluma estadounidense estará disponible en los próximos meses.
Eli Lilly (NYSE: LLY) agreed a research collaboration and licensing deal with InnoCare Pharma to pursue up to five new medicines. The partners plan to target serious conditions with limited treatment options, focusing on critical unmet medical needs. InnoCare will contribute drug discovery and early research capabilities, while Eli Lilly is set to handle broader development and commercialization. The collaboration on up to five new medicines is only one part of what could shape Eli Lilly’s...
Eli Lilly (NYSE: LLY) acordó una colaboración de investigación y un acuerdo de licencia con InnoCare Pharma para desarrollar hasta cinco nuevos medicamentos. Los socios planean abordar afecciones graves con opciones de tratamiento limitadas, centrándose en necesidades médicas críticas no cubiertas. InnoCare contribuirá al descubrimiento de fármacos y a las capacidades de investigación temprana, mientras que Eli Lilly se encargará de un desarrollo y comercialización más amplios. La colaboración en hasta cinco nuevos medicamentos es sólo una parte de lo que podría dar forma a la vida de Eli Lilly...
/PRNewswire/ -- Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) approval of Onswik™ (insulin efsitora alfa-gobe), a...
Página 25 de 68